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012.04.0Abstract Background: Pregnancy of women with heart disease is still a challenging condition
because it is associated with elevated maternal and fetal morbidity and mortality. In the clinical set-
ting, an accurate individual risk assessment is of fundamental importance.
Patients and methods: The current study was carried out in the Department of Cardiology, & the
Department of Obstetrics, El-Minia University during the period from January 2009 to December
2009. We surveyed 150 pregnant ladies with structural heart disease as a part of the Euro Heart Sur-
vey on pregnancy & heart disease; they were followed up till 6 weeks postpartum. The follow-up of
121 cases during pregnancy and postpartum period was completed; there were 23 cases still preg-
nant while the follow-up of 6 cases was missed. So we included the 121 cases in our statistical anal-
ysis regarding maternal and fetal events during pregnancy, delivery & postpartum. Inclusion
criteria: All patients with structural heart disease, valvular heart disease, congenital heart disease,
ischemic heart disease, cardiomyopathy, pulmonary hypertension presenting with pregnancy, inde-
pendent of age, any concomitant diseases and type of heart disease had been enrolled. Structural
heart disease was diagnosed through full history taking, clinical examination and investigations
such as ECG & echocardiography. Exclusion criteria: Non-structural heart disease even arrhyth-
mias occurring in the context of a normal heart. A follow-up of all patients had been performed
for at least 6 weeks after delivery using telephone contact or in our outpatient clinic (for heart dis-
ease with pregnancy) in the El-Minia University Hospital.
Results: 78% cases were with valvular heart disease, 7.3% with congenital heart disease, 10.7%
with cardiomyopathy, 2% with ischemic heart disease while 0.6% cases with Lutembacher syn-
drome and 1.3% cases with pulmonary hypertension. Maternal cardiovascular complications dur-
ing pregnancy were heart failure 6.6%, thrombotic complications: 0.8%, arrhythmia 1.6%, and
hemorrhagic complications 2.5%. Maternal mortality was 3.3%, 30.4% of the high-risk groupnt of Cardiology, Faculty of
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100 N.M. Taha et al.suffered from maternal complications in comparison to only 9.5% of the women at low-risk.
Accordingly, the high-risk group 30.4% had a 3.1-fold greater severe maternal event rate; maternal
mortality was 8.2% of the women in high-risk group versus 0% in the low-risk group. Also fetal
complications occurred in 14.3% of the high-risk group versus 0% in low-risk group. APGAR
score and birth weight were much lower in the high-risk group (p value 0.001).
Conclusions: RHD is the commonest cardiac lesion among pregnant women. Peripartum cardio-
myopathy was the 1st etiology of heart failure in our study but fortunately it had a good prognosis.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Approximately 2% of pregnancies involve maternal cardiovas-
cular disease and this poses an increased risk to both mother
and fetus. Most women with cardiovascular disease can expe-
rience pregnancy with proper care, but a careful prepregnancy
evaluation is mandatory. Sometimes, cardiac disease may
manifest for the ﬁrst time in pregnancy, because the hemody-
namic changes may compromise a limited cardiac reserve.1
Many factors ultimately determine the counseling and guid-
ance during pregnancy and the mode of delivery of individual
patients with heart disease in a given community. A multidis-
ciplinary team approach with cardiologists, obstetricians and
anesthetists during pregnancy, delivery and the postpartum
period is recommended.2 Collectively, these women have a
spectrum of structural heart disease including congenital heart
disease, rheumatic heart disease, pulmonary hypertension, car-
diomyopathy and coronary artery disease. The heterogeneous
nature of this group means that the information we use to de-
velop our management protocols is incomplete and frag-
mented. To be able to practice to the standard demanded by
an ‘‘Evidence Based Medicine’’ approach it is imperative that
we establish a prospective registry.
1.1. The aim of the study
The aim of this work is to demonstrate the variation of struc-
tural heart disease in pregnant ladies in our locality, detect
maternal & fetal complications and to predict the risk factors
for poor maternal, fetal & neonatal outcomes.
2. Methods
The current study was carried out in the Department of Cardi-
ology, and the Department of Obstetrics, El-Minia University
during the period from January 2009 to December 2009. We
surveyed 150 pregnant ladies with structural heart disease as
part of the Euro Heart Survey on pregnancy, heart disease;
they were followed up till 6 weeks postpartum. The follow-
up of 121 cases during pregnancy and postpartum period
was completed; there were 23 cases still pregnant while the fol-
low-up of 6 cases was missed. We included the 121 cases in our
study regarding maternal and fetal events during pregnancy,
delivery, and postpartum. Inclusion criteria: All patients with
structural heart disease, valvular heart disease, congenital
heart disease, ischemic heart disease, cardiomyopathy, and
pulmonary hypertension, presenting with pregnancy, indepen-
dent of age, any concomitant diseases and type of heart disease
have been enrolled. Structural heart disease was diagnosedthrough full history taking, clinical examination and investiga-
tions such as ECG & echocardiography.
Exclusion criteria: Non-structural heart disease even
arrhythmias occurring in the context of a normal heart. A fol-
low-up of all patients had been performed for at least 6 weeks
after delivery using telephone contact or in our outpatient clinic
(for heart disease with pregnancy) in the El-Minia University
Hospital. Electronic Case Report Form (CRF): [I] Patient char-
acteristics: age, gestational age, parity status, and major non-
cardiac diseases; risk factors (diabetes mellitus, hypertension
and smoking status]); New York Heart Association (NYHA)
functional class; past history relevant to the structural heart dis-
ease and obstetric history. [II] Present pregnancy: documenta-
tion of cardiac events during pregnancy (heart failure,
thrombo-embolic complications, hemorrhagic complications,
endocarditis, arrhythmias & acute coronary syndrome) and
documentation of obstetric events during pregnancy [small
for gestational age, IUFD (20 weeks gestation and before
birth), pregnancy-induced hypertension, pre-eclampsia and
eclampsia].
Pregnancy-induced hypertension was deﬁned as an increase
of 30 mmHg in systolic blood pressure and 15 mmHg in dia-
stolic blood pressure compared with baseline values.3 Pre-
eclampsia was deﬁned as gestational hypertension (systolic
blood pressureP 140 mmHg and/or diastolic blood pressur-
eP 90 mmHg on at least two occasions four hours apart after
20 weeks’ gestation, but before the onset of labor, or postpar-
tum systolic blood pressureP 140 mmHg and/or diastolic
blood pressureP 90 mmHg on at least two occasions 4 h
apart) with proteinuria (24 h urinary proteinP 300 mg, or spot
urine protein to creatinine ratioP 30 mg/mmol creatinine, or
urine dipstick proteinP 2+) or any multisystem complication
of pre-eclampsia.4 Use of cardiac medications and anticoagu-
lants. Mode and place of delivery. Complications during
delivery.
The following data regarding the neonate were documented:
Gender, number, pregnancy duration and APGAR score:
The test was done at 1 and 5 min after birth, and may be
repeated later if the score is and remains low.5 Neonatal
complications: Premature birth (<37 weeks gestation), small-
for-gestational-age birth weight (<10th percentile for gesta-
tional age), congenital heart disease in babies of mothers with
congenital heart disease by clinical examination and echocardi-
ography if indicated, respiratory distress syndrome, or neona-
tal death.3,4 Maternal and fetal outcomes after pregnancy: The
following details were documented: Maternal & neonatal
morbidity & mortality till the end of follow-up period. All
TIMI deﬁnitions take into account blood transfusions, so that
hemoglobin and hematocrit values are adjusted by 1 g/dl and
3%, respectively, for each unit of blood transfused. Therefore,
Table 1 Demographics of the study population.
Variables Total no. = 121 No. (%)
Age Mean ± SD 26.2 ± 5.2
Smoking ve 121 (100%)
History of DM
+ve 1 (0.8%)
+ve 2 (1.7%)
+ve 1 (0.8%)
Major non-cardiac diseases +ve 5 (4.1%)
NYHA Class Class I 67 (55.4%)
Class II 50 (41.3%)
Class III 4 (3.3%)
Prior intervention No intervention 100 (82.6%)
BMV 6 (5%)
Mitral valve replacement 9 (7.4%)
Aortic valve replacement 1 (0.8%)
ASD closure 2 (1.7%)
Mitral valve repair 1 (0.8%)
CABG and PCI 1 (0.8%)
Double valve replacement 1 (0.8%)
Hospital admission during pregnancy Admission due to cardiac cause 42 (34.7%)
Admission due to obstetric cause 9 (7.4%)
Place of delivery Tertiary hospital 113 (93.4%)
Regional center 7 (5.8%)
At home 1 (0.8%)
Mode of delivery Vaginal 66 (54.5%)
CS due to cardiac cause 26 (21.5%)
CS due to obstetric cause 16 (13.5%)
2ry CS due to cardiac cause 6 (5%)
2ry CS due to obstetric cause 7 (5.8%)
DM= diabetes mellitus, NYHA=New York Heart Association, AF= atrial ﬁbrillation, PSVT = paroxysmal supraventricular tachycardia,
BMV= balloon mitral valvuloplasty, CABG= coronary artery bypass graft, PCI = percutaneous coronary intervention. PASP = pulmonary
artery systolic pressure.
Structural heart disease in pregnancy in El-Minia localities 101the true change in hemoglobin or hematocrit if there has been
an intervening transfusion between two blood measurements is
calculated as follows: DHemoglobin = [baseline Hgb  post-
transfusion Hgb] + [number of transfused units]; DHemato-
crit = [baseline Hct  post-transfusion Hct] + [number of
transfused units · 3].6 Pulse rate of <60 is considered asystole
in a neonate. The test was done at 1 and 5 min after birth, and
may be repeated later if the score is and remains low.5 To
investigate the relationship between the severity of maternalTable 2 Cardiac medications & investigations.
Variables Total no. =
Cardiac medications Beta block
Diuretics
ACEIs
Ca antago
Digoxin
Anticoagu
Anticoagu
PASP Mean ± S
Pulmonary hypertension 1ry pulmo
2ry pulmo
Ejection fraction Mean ± S
ECG Sinus
AF
PSVT
Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 wee
Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeksheart disease and maternal and fetal/neonatal, patients were
divided into a high and low-risk groups according to ACC/
AHA 2006 guidelines for the management of patients with val-
vular heart disease.7
2.1. Statistical analyses
Discrete values were presented as counts and percentages.
Values were expressed as mean ± SD. Signiﬁcance was121 No. (%)
ers 20 (16.5%)
19 (15.7%)
1 (0.8%)
nist 6 (5%)
7 (5.8%)
lant regimen I 8 (6.6%)
lant regimen II 8 (6.6%)
D 43.5 ± 21.9
nary hypertension 2 (1.6%)
nary hypertension 67 (55.3%).
D 61.4 ± 8.5
114 (94.2%)
5 (4.1%)
2 (1.7%)
ks prepartum).
prepartum covered by heparin).
41.3%
3.3%
55.4%
Class I Class II Class III
Figure 1 NYHA class.
102 N.M. Taha et al.determined using the t-test. A probability level of p< 0.05 was
considered signiﬁcant. A student unpaired t-test was used to
analyze differences between patient groups. Data were
analyzed by SPSS software version 13 (Statistical Package
for the Social Science).
3. Results
The results of the study are arranged into these items:
– Demographics of the study population.
– Pregnancy course.
– Delivery and outcome.Table 3 Prevalence of cardiac disease in pregnancy.
Variables Total
no. = 150
No. (%)
[1] Valvular heart disease Total = 117 78
MS 20 13.3
MR 25 16.6
Mixed MS & MR 46 30.6
AS 3 2
AR 3 2
Mixed AS & AR 2 1.3
PS 3 2
Mechanical prosthesis 15 10
[2] Congenital heart disease Total = 11 7.3
ASD 6 4
VSD 1 0.66
Aortic coarctation 1 0.66
Subaortic membrane 2 1.3
Eisenmenger’s syndrome 1 0.66
[3] Cardiomyopathy Total = 16 10.7
Peripartum cardiomyopathy 13 8.66
Dilated cardiomyopathy 1 0.66
Hypertrophic obstructive
cardiomyopathy
1 0.66
Hypertrophic non-obstructive
cardiomyopathy
1 0.66
[4] Ischemic heart disease 3 2
[5] Combined congenital heart
disease and rheumatic heart disease
(Lutembacher syndrome)
1 0.66
[6] Pulmonary hypertension 2 1.3
Idiopathic pulmonary arterial hypertension 1 0.66
Pulmonary embolism 1 0.66
MS=mitral stenosis, MR=mitral regurgitation, AS = aortic
stenosis, AR= aortic regurgitation, PS = pulmonary stenosis,
ASD= atrial septal defect, VSD= ventricular septal defect.– Predictors of poor maternal outcome.
– Predictors of poor fetal & neonatal outcomes.
The baseline characteristics of the study population are
shown in Table 1.
Anticoagulation was indicated in 16 cases: 10 cases with
mechanical valve prostheses, 3 cases with AF, a case with se-
vere 1ry pulmonary hypertension, a case had RHD associated
with antiphospholipid antibody syndrome, history of CV,
stroke & recurrent abortions. Patients are classiﬁed as regards
anticoagulation during 1st trimester of pregnancy into two
groups:
Group I: 8 patients with regimen I anticoagulation
(unfractionated heparin 1st trimester and 2 weeks prepartum).
Group II: 8 patients with regimen II anticoagulation
(warfarine throughout the pregnancy with 2 weeks prepartum
covered by heparin).
The cardiac medications & investigations of the study
population are shown in Table 2.
The classiﬁcation of the study population according to
NYHA class are shown in Fig. 1
Variation of structural heart disease in pregnant patients in
El-Minia locality: In total, 117 (78%) cases had valvular heart
disease, 11 (7.3%) had congenital heart disease, 16 (10.7%)
had cardiomyopathy, 3 (2%) had ischemic heart disease, while
1 (0.6%) case had Lutembacher syndrome and 2 (1.3%) cases
were with pulmonary hypertension (Table 3).
Pregnancy course: (A) Maternal cardiovascular complica-
tions: (1) Heart failure 6.6%: During pregnancy 6 women
had left sided heart failure (3 cases had peripartum cardiomy-
opathy, 2 cases had RHD with moderate to severe MS, 1 case
had severe AS, the case who had severe primary pulmonary
hypertension (PASP = 110 mmHg), the last case had dilated
cardiomyopathy). (2) Thrombotic complications 0.8%: OneTable 4 Complications during pregnancy.
Complications Total no. = 121
No. (%)
Cardiovascular complications
[1] Heart failure
Left sided failure & acute pulmonary edema 6 (5%)
Right ventricular failure 1 (0.8%)
Cardiogenic shock 1 (0.8%)
[2] Thromboembolic complications 1 (0.8%)
[3] Hemorrhagic complications 3 (2.5%)
[4] Arrhythmias
Newly developed AF 2 (1.7%)
PSVT 1 (0.8%)
[5] Acute coronary syndrome 0
[6] Endocarditis 0
Obstetric complications
[1] IUGR 5 (4.1%)
[2] IUFD 6 (5%)
[3] Pregnancy induced hypertension 1 (0.8%)
[4] Preeclampsia 9 (7.4%)
[5] Eclampsia 0
[6] PROM 4 (3.3%)
[7] Spontaneous abortion 8 (6.6%)
IUGR= intra-uterine growth retardation, IUFD= intra-uterine
fetal death, PROM= premature rupture of membrane.
Table 5 Maternal complications during delivery and maternal
mortality.
Total no. = 121 No. (%)
Maternal complications during delivery
No 101 (83.5%)
Acute heart failure 16 (13.2%)
Hemorrhagic complications 1 (0.8%)
Cardiogenic shock 1 (0.8%)
Hemorrhagic complications and
acute pulmonary edema
1 (0.8%)
Acute ST segment elevation
myocardial infarction
1 (0.8%)
Maternal mortality
No 117 (96.7%)
Due to cardiac causes 3 (2.4%)
Due to other causes 1 (0.8%)
Structural heart disease in pregnancy in El-Minia localities 103case had thrombosis of the mitral valve prosthesis, she was on
suboptimum anticoagulation. (3) Arrhythmia 1.6%: One case
recently developed atrial ﬁbrillation while another case had
an attack of paroxysmal supraventricular tachycardia. (4)
Hemorrhagic complications 2.5%: All the hemorrhagic com-
plications during pregnancy were minor bleeding according
to TIMI classiﬁcation. (5) There were no cases of endocarditis:
All cases had received prophylaxis against infective endocardi-
tis (Table 4).
All cases with cardiovascular complications responded sat-
isfactorily to clinical management and intervention during
pregnancy was not indicated.
(B) Therapeutic abortion: Termination of pregnancy in the
1st trimester. Therapeutic abortion was indicated in 4% (3%
due to cardiac indication and 1% due to obstetric indication).
First case had subaortic membrane causing severe LVOT
obstruction (peak & mean PGs were 120 & 70 mmHg, respec-
tively), 2nd case had RHD with severe MR & moderate to se-
vere MS. She was in NYHA class III in 6th week of
gestation. Functional capacity was conﬁrmed by exercise test-
ing before the decision of termination. The indication of ther-
apeutic abortion in the 3rd case was severe pulmonary
hypertension (PASP = 110 mmHg), patient had RHD with
moderate to severe MS. The last case was due to fetal
malformation.
Delivery and outcome: (A) Place of delivery: 93.4% were in
tertiary hospital (University Hospitals) while 5.8% were in re-
gional centers & 0.8% delivered at home. (B) Mode of deliv-
ery: 54.5% of cases were delivered vaginally, while 45.5%
delivered by CS, 26.5% due to cardiac indication & 19% were
due to obstetric cause.
(C) Maternal complications during delivery (Table 5):
– Acute heart failure & cardiogenic shock (16 cases).
– Acute myocardial infarction (1 case).
(D) Maternal mortality 3.3% (4 patients). (E) Neonatal
outcome (Table 6):
 Two mothers with congenital heart disease had neonates
with ASD.
 Three cases had neonatal respiratory distress & neonatal
ICU admission with 1 (0.8%) case had neonatal mortality.
Heart failure complications were found in 19.7% of
pregnant women with heart disease during pregnancy and
peripartum period. We found the following: 54.2% were
with peripartum cardiomyopathy, 29% with RHD, 4.2%
with idiopathic dilated cardiomyopathy, 4.2% with
Eisenmenger’s syndrome, and 8.4% with severe pulmonary
hypertension.
Predictors of poor maternal outcome (Table 7): (A) Predic-
tors of maternal mortality: Mean maternal age was = 26 ±
5.2:
[1] PASP = 74.5 ± 24.6 (p= 0.004) (50% 1ry PH & 50%
2ry PH).
[2] NYHA classiﬁcation (75% II & III) (p= 0.03).
[3] AF (25%) (p= 0.02).
[4] Anticoagulation during pregnancy (75%) (p= 0.004).
75% (3 cases) were on anticoagulant therapy due to
the high risk underlying lesions.(B) Predictors of heart failure:
[1] Maternal age 30 ± 7.3 (p= 0.001). Maternal par-
ity = 3.3 ± 2.8 (p= 0.02) (Table 8).
[2] NYHA class (62.5% II & III) (p= 0.001).
[3] Pulmonary hypertension (50%) [10% 1ry & 40% 2ry]
(p= 0.1) non-signiﬁcant.
[4] Ejection fraction = 53.1 ± 13.3 (p= 0.004).
(C) Predictors of thrombotic complications: Mechanical
prosthetic valve requiring anticoagulation (Table 9).
(D) Predictors of hemorrhagic complications: Anticoagula-
tion therapy (66.7%, p= 0.004) (Table 10).
Predictors of poor fetal & neonatal outcomes (Table 11):
(A) Predictors of IUFD:
[1] NYHA class (50% II & III) (p= 0.001).
[2] PASP = 65.1 ± 33.8 (p= 0.01)
[3] Anticoagulation therapy (p= 0.004).
[4] Pre-eclampsia was present in 33.3% of cases but had
non-signiﬁcant p value (p= 0.06).
(B) Predictors of IUGR:
[1] EF = 51.4 ± 12.03 (p= 0.007).
[2] NYHA class (20% II & 60% III) (p= 0.004).
[3] Preeclampsia (40%) (p= 0.04).
[4] Pulmonary hypertension (60% of cases) 20% 1ry & 40%
2ry (p= 0.03).
30.4% of the high-risk group suffered from maternal com-
plications in comparison to only 9.5% of the women at low-
risk. Accordingly, the high-risk group (30.4%) had a 3.1-fold
greater severe maternal event rate; maternal mortality was
8.2% of the women in high-risk group versus 0% in the low-
risk group. Also fetal complications occurred in 14.3% of
the high-risk group versus 0% in low-risk group. APGAR
score & birth weight were much lower in the high-risk group
(p value 0.001). The majority of cases (83.7%) in the high-risk
group conceived without preconceptional counseling. As re-
gards signiﬁcance of preconceptional counseling and precon-
ceptional NYHA class, we found the following: There were 4
cases with NYHA III preconceptionally.
Table 6 Perinatal outcomes.
Outcome Total no. = 121
Gender and number
of outcome
Dead unknown gender 14 (11.6%)
Single male 59 (48.8%)
Single female 46 (38%)
Twins male 2 (1.7%)
Congenital heart
diseases
No 117 (96.7%)
ASD 2 (1.7%)
Unknown 2 (1.7%)
Yes 2 (1.7%)
Mean ± SD 2513.7 ± 922.2
Mean ± SD 6.9 ± 2.8
104 N.M. Taha et al.Therapeutic abortion was indicated in 2 cases with NYHA
class III presented to us early in 1st trimester. In another case
complicated by acute pulmonary edema, mechanical ventila-
tion was indicated. The last case was complicated with CHF,
cardiogenic shock & IUFD (Tables 12 and 13).Table 7 The relation between patient characteristics and maternal
Patient characteristics Matern
+ve n
Maternal age 26 ± 5
Parity 0–4
2 ± 1.
Hypertension 0
Atrial ﬁbrillation 1 (25%
Prior intervention
No intervention 4 (100%
BMV 0
Mitral valve replacement 0
Aortic valve replacement 0
ASD closure 0
Mitral valve repair 0
CABG and PCI 0
Double valve replacement 0
Beta blockers 1 (25%
Diuretics 1 (25%
Ca antagonist 1 (25%
Digoxin 1 (25%
Anticoagulant
1. No 1 (25%
2. Anticoagulant regimen I 2 (50%
3. Anticoagulant regimen II 0
4. Anticoagulant started after ﬁrst trimester 1 (25%
PASP 74.5 ±
Pulmonary hypertension
No 0
1ry 2 (50%
2ry 2 (50%
Ejection fraction mean ± SD 65.5 ±
NYHA class
Class I 1 (25%
Class II 2 (50%
Class III 1 (25%
Pre eclampsia: present 1 (25%
Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 wee
Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks4. Discussion
Structural heart disease with pregnancy in El-Minia locality in
this study was 1.66 per 100 deliveries in the period from 1 Jan-
uary 2009 to 12 December 2009. In western countries, mater-
nal heart disease complicates 1–3% of pregnancies.1,8 This
study in El-Minia locality, demonstrated that RHD was
responsible for the majority (66.7%) of the cases of heart dis-
ease in pregnancy, while congenital heart diseases represented
7.3% & cardiomyopathies represented 10.7%. In Sa˜o Paulo,
Brazil, Avila et al. documented in their study that the incidence
of rheumatic heart disease was 55.7%, while congenital heart
disease represented 19.1% and cardiomyopathies were
4.3%.9 In European countries, congenital heart diseases were
responsible for the majority of the cases of heart disease with
pregnancy in the Euro-Heart survey, congenital heart disease
(65%), valvular heart disease (25%), cardiomyopathy (1%)
and IHD (5%).10,16 Regimen I anticoagulation was associated
with (25%) fetal loss and surprisingly 0% maternal thrombotic
complications, while regimen II anticoagulation was associated
with 50% fetal loss and 12.5% maternal thrombotic complica-mortality.
al mortality
o. = 4 ve no. = 117 p value
.2 26.2 ± 5.3 0.9
0–10 0.8
8 1.8 ± 2.06
2 (1.7%) 0.9
) 4 (3.4%) 0.02
) 96 (82.1%) 0.9
6 (5.1%)
9 (7.7%)
1 (0.9%)
2 (1.7%)
1 (0.9%)
1 (0.9%)
1 (0.9%)
) 19 (16.2%) 0.5
) 18 (15.4%) 0.5
) 5 (4.3%) 0.1
) 6 (5.1%) 0.2
0.004
) 103 (88%)
) 6 (5.1%)
8 (6.8%)
) 0
24.6 42.5 ± 21.1 0.004
52 (44.4%) 0.002
) 10.91%)
) 64 (54.7%)
10.8 61.7 ± 8.4 0.3
) 66 (56.4%) 0.03
) 48 (41%)
) 3 (2.6%)
) 8 (6.8%) 0.2
ks prepartum).
prepartum covered by heparin).
Table 8 The relation between patients characteristics and heart failure during pregnancy.
Patient characteristics Heart failure
Present no. = 8 Absent no. = 113 p value
Maternal age 30.2 ± 8.2 25.9 ± 4.9 0.02
Parity 3.3 ± 2.8 1.7 ± 1.9 0.02
Hypertension 0 2 (1.8%) 0.9
Atrial ﬁbrillation 0 2 (1.8%) –
Prior intervention
No intervention 8 (100%) 92 (81.4%) 0.9
BMV 0 6 (5.3%)
Mitral valve replacement 0 9 (8%)
Aortic valve replacement 0 1 (0.9%)
ASD closure 0 2 (1.8%)
Mitral valve replacement 0 1 (0.9%)
CABG and PCI 0 1 (0.9%)
Double valve replacement 0 1 (0.9%)
Beta blockers 1 (12.5%) 19 (16.8%) 0.9
Diuretics 5 (62.5%) 14 (12.4%) 0.002
Ca antagonist 2 (25%) (3.5%) 0.05
Digoxin 0 7 (6.2%) 0.9
PASP 53.6 ± 33.9 42.8 ± 20.9 0.1
Pulmonary hypertension
no 4 (50%) 48 (42.5%) 0.1
1ry 1 (12.5%) 2 (1.8%)
2ry 3 (37.5%) 63 (55.8%)
Ejection fraction 53.1 ± 13.3 61.9 ± 7.8 0.004
NYHA class
Class I 3 (37.5%) 64 (56.6%) 0.001
Class II 3 (37.5%) 47 (41.6%)
Class III 2 (25%) 2 (1.8%)
Pre eclampsia 1 (12.5%) 8 (7.1%) 0.8
Structural heart disease in pregnancy in El-Minia localities 105tions. This strange result may be due to negligence & lack of
regular follow-up of INR in regimen II while all patients in
group I were admitted to hospital with proper heparin dose
adjustment guided with aPTT. Gelson et al.11 found that hep-
arin for 6–12 weeks, followed by warfarine to 38 weeks, fol-
lowed by LSCS was associated with 9% maternal
thromboembolism & 30% fetal loss with 0% fetal abnormal-
ity. While warfarine until 38 weeks, followed by elective LSCS
was associated with 4% maternal thromboembolism & 30%
fetal loss with 6% fetal abnormality. Our results were in dis-
agreement with Stangl et al.,10 who documented a 12.9% inci-
dence of maternal cardiovascular events during pregnancy in
women with congenital and acquired heart disease. However
Koregol et al.12 found that the incidence of cardiac complica-
tions was 18%. In our study left sided heart failure occurred in
4.9% during pregnancy while it occurred in 13.2% during
delivery, cardiogenic shock occurred in 0.8% during preg-
nancy, while it occurred in 1.6% during delivery & early post-
partum period. However in a study done by Koregol et al.12 in
Karnataka state, India, the incidence of pulmonary edema
during pregnancy was 10.9%. In disagreement with our results
in a study done by Stangl et al.,10 the incidence of heart failure
was 6.5%. In our study there was one case 0.8% who had life
threatening thrombosis of the mitral valve prosthesis. In agree-
ment with our results Siu et al.13 documented that embolic
strokes occurred in 0.7% of pregnancies. However Stangl
et al.10 found a higher incidence of severe thrombotic compli-
cations, 2.2%. In our study there was 0.8% newly developed
atrial ﬁbrillation and 0.8% paroxysmal supraventricular tachy-cardia. However Koregol et al.12 mentioned that the incidence
of atrial ﬁbrillation was 2.7%. Infective endocarditis in our
study was 0%. In agreement with our results Stangl et al.10
found the same incidence. While Avila et al.9 found that the
incidence was 0.5%. In disagreement with our results Koregol
et al.12 found that bacterial endocarditis occurred in 4.5% of
cases. Maternal mortality, in our study was 3.3% maternal
deaths 2.5% due to cardiac causes while 0.8% due to other
causes. This was comparable with Koregol et al.,12 who re-
ported 3.6% maternal deaths. In disagreement with our results
Stangl et al.10 reported that maternal mortality was 1.1%,
while the Eurobservational Research Programme 2010 found
HF: 11%, AF: 2%, ventricular arrhythmia: 1%, hemorrhagic
complication: 1%, ACS: 0.5%, thrombo-embolic events:
0.3%, and endocarditis: 0.2%.16
Mode of delivery: In our study 54.5% of cases were deliv-
ered vaginally, while 45.5% were delivered by CS. 26.5%
due to cardiac indication and 19% were due to obstetric cause.
However Koregol12 reported that the majority of cases deliv-
ered vaginally 72.8% and cesarean section 27.2% was done
for obstetric indications only. Avila et al.9 reported that vagi-
nal delivery occurred in 65% patients and cesarean section in
35% women, while Eurobservational Research Programme
2010 found vaginal delivery represented 54%, and cesarian
46%.16
In our study fetal and neonatal outcomes were 4.1% small
for gestational age, 5% IUFD, 1.7% congenital heart diseases
in neonates, 0.8% neonatal ICU admission with respiratory
and 1.7% neonatal mortality with respiratory distress. Birth
Table 9 The relation between patient characteristics and thromboembolic complications.
Patient characteristics Thromboembolic complications
Present no. = 1 Absent no. = 120 p value
Maternal age 20 ± 0 26.2 ± 5.2 0.2
Parity 0 1.8 ± 2.04 –
Atrial ﬁbrillation 0 2 (1.7%) –
Prior intervention
No intervention 0 100 (83.3%) 0.08
BMV 0 6 (5%)
Mitral valve replacement 1 (100%) 8 (6.7%)
Aortic valve replacement 0 1 (0.8%)
ASD closure 0 2 (1.7%)
Mitral valve replacement 0 1 (0.8%)
CABG and PCI 0 1 (0.8%)
Double valve replacement 0 1 (0.8%)
Anticoagulant 0.002
1. No 0 104 (86.7%)
2. Anticoagulant regimen I 0 8 (6.7%)
3. Anticoagulant regimen II 1 (100%) 7 (5.8%)
4. Anticoagulant started after ﬁrst trimester 0 1 (0.8%)
PASP 81 43.2 ± 21.7 0.08
Pulmonary hypertension
No 0 52 (43.3%) 0.6
1ry 0 3 (2.5%)
2ry 1 (100%) 65 (54.2%)
Ejection fraction 74 ± 0 61.3 ± 8.4 0.1
NYHA class
Class I 1 (100%) 66 (55%) 0.6
Class II 0 50 (41.7%)
Class III 0 4 (3.3%)
Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum).
Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin).
Table 10 The relation between patients characteristics and hemorrhagic complications.
Patients characteristics Hemorrhagic complications
Present no. = 3 Absent no. = 118 p value
Maternal age 30.3 ± 9.5 26.1 ± 5.1 0.1
Parity 4 ± 2.6 1.7 ± 2.1 0.06
Hypertension: 0 2(1.7%) 0.9
Atrial ﬁbrillation 1 (33.3%) 1 (0.8%) 0.06
Prior intervention
No intervention 3 (100%) 97 (82.2%) 0.9
BMV 0 6 (5.1%)
Mitral valve replacement 0 9 (7.6%)
Aortic valve replacement 0 1 (0.8%)
ASD closure 0 2 (1.7%)
Mitral valve replacement 0 1 (0.8%)
CABG and PCI 0 1 (0.8%)
Double valve replacement 0 1 (0.8%)
Anticoagulant 0.004
1. No 1 (33.3%) 103 (87.3%)
2. Anticoagulant regimen I 2 (66.7%) 6 (5.1%)
3. Anticoagulant regimen II 0 8 (6.8%)
4. Anticoagulant started after ﬁrst trimester 0 1 (0.8%)
PASP 31 ± 13.8 43.9 ± 22.07 0.3
Pulmonary hypertension
No 1 (33.3%) 51 (43.2%) 0.8
1ry 0 3 (2.5%)
2ry 2 (66.7%) 64 (54.2%)
Ejection fraction 65.3 ± 3.5 61.3 ± 8.6 0.4
Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum).
Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin.
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Table 11 The relation between patients characteristics and IUFD.
Patients characteristics IUFD
Present no. = 6 Absent no. = 115 p value
Maternal age 26.1 ± 8.2 26.2 ± 5.1 0.9
Parity 2.5 ± 2.5 1.8 ± 2.02 0.4
Hypertension 0 2 (1.7%) 0.1
Atrial ﬁbrillation 0 2 (1.7%) –
Prior intervention
No intervention 5 (83.3%) 95 (82.6%) 0.9
BMV 0 6 (5.2%)
Mitral valve replacement 1 (16.7%) 8 (7%)
Aortic valve replacement 0 1 (0.9%)
ASD closure 0 2 (1.7%)
Mitral valve replacement 0 1 (0.9%)
CABG and PCI 0 1 (0.9%)
Double valve replacement 0 1 (0.9%)
Beta blockers 0 20 (17.4%) 0.5
Diuretics 2 (33.3%) 16 (13.9%)
Ca antagonist 1 (16.7%) 5 (4.3%) 0.2
Digoxin 1 (16.7%) 6 (5.2%) 0.3
Anticoagulant 0.004
1. No 3 (50%) 101 (87.8%)
2. Anticoagulant regimen I 0 8 (7%)
3. Anticoagulant regimen II 2 (33.3%) 6 (5.2%)
4. Anticoagulant started after ﬁrst trimester 1 (16.7%) 0
PASP 65.1 ± 33.8 42.4 ± 20.7 0.01
Pulmonary hypertension
No 2 (33.3%) 50 (43.5%) 0.07
1ry 1 (16.7%) 2 (1.7%)
2ry 3 (50%) 63 (54.8%)
Ejection fraction 58.5 ± 12.9 61.5 ± 8.3 0.3
NYHA class
Class I 3 (50%) 64 (55.7%) 0.001
Class II 1 (16.7%) 49 (42.6%)
Class III 2 (33.3%) 2 (1.7%)
Pre eclampsia 2 (33.3%) 7 (6.1%) 0.06
Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum).
Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin).
Table 12 The relation between patients characteristics and IUGR.
Patients characteristics IUGR
Present no. = 5 Absent no. = 116 p value
Maternal age 29.4 ± 8.2 26.09 ± 5.1 0.1
Parity 2.6 ± 2.7 1.8 ± 2.02 0.3
Atrial ﬁbrillation 0 2 (1.7%) –
Beta blockers 1 (20%) 19 (16.4%) 0.9
Diuretics 2 (40%) 14 (14.7%) 0.1
Ca antagonist 1 (20%) 5 (4.3%) 0.2
Digoxin 0 7 (6%) 0.9
PASP 50.2 ± 35.7 43.3 ± 21.3 0.4
Pulmonary hypertension
No 2 (40%) 50 (43.1%) 0.03
1ry 1 (20%) 2 (1.7%)
2ry 2 (40%) 64 (55.2%)
Ejection fraction 51.4 ± 12.03 61.5 ± 8.1 0.007
NYHA class
Class I 1 (20%) 66 (56.9%) 0.004
Class II 1 (20%) 49 (42.2%)
Class III 3 (60%) 1 (0.9%)
Pre eclampsia 2 (40%) 7 (6%) 0.04
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Table 13 The relation between maternal and fetal risk and the complications during pregnancy and delivery.
Complications Maternal and fetal risk (no = 102)
Low no. = 53 High no. = 49 p value
Maternal complication during delivery 0.8
Acute heart failure 1 (1.9%) 6 (12.2%)
Hemorrhagic complications 0 1 (2%)
Cardiogenic shock 0 1 (2%)
Heart failure 0 4 (8.2%) –
Thromboembolic complications 0 1 (2%) –
Hemorrhagic complications 3 (5.7%) 0 –
Arrhythmia
AF 1 (1.9%) 1(2%) 0.6
PSVT 0 1 (2%)
Preeclampsia 2 (3.8%) 2 (4.1%) 0.3
IUGR 0 3 (6.1%) –
IUFD 0 4 (8.2%) –
Maternal mortality 0 4 (8.2%) –
Neonatal mortality 0 0 –
APGAR score (mean ± SD) 7.9 ± 1.6 5.8 ± 3.6 0.002
Birth weight (mean ± SD) 2805.4 ± 551.4 2201.02 ± 1180.4 0.001
Preconceptional counseling 0.002
No 21 (39.6%) 41 (83.7%)
Planned pregnancy after counseling 32 (60.4%) 6 (12.2%)
Undesired pregnancy 0 2 (4.1%)
108 N.M. Taha et al.weight was 2513.7 ± 922.2. Koregol et al.12 reported that the
incidence of IUFD/still birth was 6.8%, small for gestational
age was 46.3%, congenital heart disease of baby was 0%.
Mean birth weight was 2.54 kg, and 30.1% babies required
neonatal intensive care unit admission. Neonatal death was
2.9%,12 while Eurobservational Research Programme 2010
found neonatal mortality as 0.46% and mean birth weight
3 kg.16
In our study 44.6% of cases were symptomatic (41.3%
NYHA functional class II & 3.3% NYHA class III). Both
maternal morbidity and mortality are high in pregnant women
with poor functional class. 75% of maternal mortality was
NYHA class II & III (p= 0.02). In agreement with our results
Sawhney et al.14 showed that eight of 10 maternal deaths
(80%) occurred in patients with NYHA class III and IV. Also
in agreement with our results Koregol et al.12 showed that pa-
tients with NYHA class III and IV had the worst maternal and
perinatal outcomes. Bonow et al.7 classiﬁed valvular heart le-
sions according to maternal, fetal, and neonatal risks into
high-risk & low-risk groups. In our study, a total of 30.4%
of the high-risk group suffered from maternal complications
in comparison to only 9.5% of the women at low-risk; mater-
nal mortality was 8.2% of the women in high-risk group versus
0% in the low-risk group. Also fetal complications occurred in
14.3% of the high-risk group versus 0% in low-risk group. AP-
GAR score & birth weight were much lower in the high-risk
group (p value 0.001). The majority of cases (83.7%) in the
high-risk group conceived without preconceptional counseling.
In agreement with our results Drenthen et al.15 reported that
mechanical valve prosthesis is one of the predictors of mater-
nal cardiac complications. In our study we reported the follow-
ing predictors of poor maternal outcome. Maternal age
30.2 ± 8.2 (p= 0.02), parity 3.3 ± 2.8 (p= 0.02), NYHA
functional classP II (p= 0.001), severe pulmonary hyperten-
sion 74.5 ± 24.6 (p= 0.002), atrial ﬁbrillation (p= 0.02),
mechanical prosthesis requiring anticoagulation (p= 0.002)and ejection fraction 53.1 ± 13.3 (p= 0.004). Also we re-
ported the following predictors of poor fetal/neonatal out-
come: NYHA functional classP II (p= 0.004), pulmonary
hypertension (p= 0.03), ejection fraction 51.4 ± 12.03
(p= 0.007), preeclampsia (p= 0.04) and anticoagulation
(p= 0.004). However Siu et al.13 reported the following pre-
dictors of cardiac complications, prior cardiac event or
arrhythmia (p< 0.001), NYHA functional class > II or
cyanosis (p= 0.009), left heart obstruction (p< 0.001) and
systemic ventricular dysfunction (p< 0.001).
5. Conclusions
RHD is the commonest cardiac lesion among pregnant
women. Peripartum cardiomyopathy was the 1st etiology of
heart failure in our study but fortunately it had a good prog-
nosis, so assessment of the preconceptional functional class
of the women with structural heart disease is so important be-
cause it has an obvious impact on the maternal and fetal mor-
bidity and mortality, as well as in decision of continuation or
termination of the pregnancy.
6. Recommendations
Preconceptional counseling and planned pregnancy after risk
stratiﬁcation of every lady with structural heart disease in
the child bearing period is very important to reduce the
maternal and fetal morbidity and mortality. Further trials
are needed to determine the exact etiologic mechanism of peri-
partum cardiomyopathy. Is it a myocarditis or cardiotropic
viral infection? So endomyocardial biopsies, serum autoanti-
bodies should be searched for, also other pro-inﬂammatory
markers and cytokines. Pregnancy is contraindicated and ter-
mination of pregnancy is recommended in the following
conditions:
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sure > 75% of systemic systolic pressure). Especially idio-
pathic pulmonary arterial hypertension and Eisenmenger’s
syndrome.
 Dilated cardiomyopathy with congestive heart failure.
 Cyanotic congenital heart disease.
 Severe symptomatic stenotic valve disease, which cannot be
treated using percutaneous procedures.
 Severe MR and AR with LV dysfunction (LVEF < 40%).
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